Pneumonia Therapeutics Market by Drug Class (Antibacterial Drugs, Antifungal Drugs, Antiviral Drugs), Pneumonia Type (Community-acquired pneumonia (CAP), Hospital-acquired pneumonia (HAP), Ventilator-associated pneumonia (VAP)), Age Group, Distribution Ch

Pneumonia Therapeutics Market by Drug Class (Antibacterial Drugs, Antifungal Drugs, Antiviral Drugs), Pneumonia Type (Community-acquired pneumonia (CAP), Hospital-acquired pneumonia (HAP), Ventilator-associated pneumonia (VAP)), Age Group, Distribution Channel - Global Forecast 2024-2030


The Pneumonia Therapeutics Market size was estimated at USD 15.34 billion in 2023 and expected to reach USD 16.64 billion in 2024, at a CAGR 8.93% to reach USD 27.93 billion by 2030.

Global Pneumonia Therapeutics Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pneumonia Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pneumonia Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pneumonia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Allergan plc, AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Biobrick Pharma, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lincoln Pharmaceuticals Ltd., Lupin Pharmaceuticals, Inc., Mankind Pharma Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Seqirus UK Limited by CSL Limited, Serum Institute of India, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Wellona Pharma, and Zydus Healthcare Limited.

Market Segmentation & Coverage

This research report categorizes the Pneumonia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
Antibacterial Drugs
Antifungal Drugs
Antiviral Drugs
Pneumonia Type
Community-acquired pneumonia (CAP)
Hospital-acquired pneumonia (HAP)
Ventilator-associated pneumonia (VAP)
Age Group
Adult
Geriatric
Pediatrics
Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Pneumonia Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pneumonia Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Pneumonia Therapeutics Market?
4. What is the market share of the leading vendors in the Pneumonia Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Pneumonia Therapeutics Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Pneumonia Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of pneumonia and the need for efficient treatment
5.1.1.2. Significant investments in research & development of pneumonia-therapeutics
5.1.1.3. Increasing availability of generic and cost-effective pneumonia drugs
5.1.2. Restraints
5.1.2.1. Prolonged treatment duration for pneumonia
5.1.3. Opportunities
5.1.3.1. Emerging technologies to improve diagnosis and treatment of pneumonia
5.1.3.2. Growing emphasis on personalized medicine for the production of efficient drugs
5.1.4. Challenges
5.1.4.1. Potential side effects associated with certain pneumonia therapies
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Pneumonia Therapeutics Market, by Drug Class
6.1. Introduction
6.2. Antibacterial Drugs
6.3. Antifungal Drugs
6.4. Antiviral Drugs
7. Pneumonia Therapeutics Market, by Pneumonia Type
7.1. Introduction
7.2. Community-acquired pneumonia (CAP)
7.3. Hospital-acquired pneumonia (HAP)
7.4. Ventilator-associated pneumonia (VAP)
8. Pneumonia Therapeutics Market, by Age Group
8.1. Introduction
8.2. Adult
8.3. Geriatric
8.4. Pediatrics
9. Pneumonia Therapeutics Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Americas Pneumonia Therapeutics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Pneumonia Therapeutics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Pneumonia Therapeutics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Allergan plc
14.1.3. AstraZeneca PLC
14.1.4. Aurobindo Pharma Limited
14.1.5. Bayer AG
14.1.6. Biobrick Pharma
14.1.7. Cipla Limited
14.1.8. Dr. Reddy's Laboratories Ltd.
14.1.9. Eli Lilly and Company
14.1.10. F. Hoffmann-La Roche Ltd.
14.1.11. GlaxoSmithKline PLC
14.1.12. Hikma Pharmaceuticals PLC
14.1.13. Lincoln Pharmaceuticals Ltd.
14.1.14. Lupin Pharmaceuticals, Inc.
14.1.15. Mankind Pharma Ltd.
14.1.16. Merck & Co., Inc.
14.1.17. Novartis AG
14.1.18. Pfizer Inc.
14.1.19. Sanofi S.A.
14.1.20. Seqirus UK Limited by CSL Limited
14.1.21. Serum Institute of India
14.1.22. Sun Pharmaceutical Industries Ltd.
14.1.23. Teva Pharmaceutical Industries Ltd.
14.1.24. Viatris Inc.
14.1.25. Wellona Pharma
14.1.26. Zydus Healthcare Limited
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. PNEUMONIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. PNEUMONIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. PNEUMONIA THERAPEUTICS MARKET DYNAMICS
FIGURE 7. PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2023 VS 2030 (%)
FIGURE 10. PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
FIGURE 12. PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. PNEUMONIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. PNEUMONIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings